Ozempic
Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes, and an anti-obesity medication used for weight management. It can be administered by subcutaneous injection or taken orally. It is sold as a generic drug by several drug companies in the Indian and Canadian markets, and worldwide by its originator, Novo Nordisk, under the brand names Ozempic and Rybelsus for diabetes; under the brand name Wegovy for weight management; and under the brand names Wegovy and Kayshild for the treatment of metabolic-associated steatohepatitis and liver cirrhosis. Wegovy is also used to reduce the risk of heart attacks.
Beyond's analysis on Ozempic
- — Novo Nordisk faces market skepticism as long-term growth targets fail to ignite investor enthusiasm
- — GLP-1 weight-loss drugs face scrutiny over reported side‑effects like ‘Ozempic face’ and hair loss
Recent news mentioning Ozempic
- — Novo Nordisk stock tumbles as Ozempic maker sets out 2030 goals
- — Ozempic-maker turns to Anthropic to turbocharge medical research
- — Beyond "Ozempic Face": New Review Finds Nutrition May Be the Missing Piece in GLP-1 Skin Changes
- — Meant Health Expands Telehealth Access to FDA-Approved GLP-1 Prescriptions, Including Ozempic®
- — Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic
- — Ozempic maker Novo Nordisk downgraded to sell after 70% stock-price dive from peak